Every RIPTA route tells a story. Is the General Assembly listening?
A new study for the Rhode Island Public Transit Authority (RIPTA) is supposed to identify possibilities for cutting overhead costs in the name of 'efficiency.' A recently released chapter of the report attempts to classify the impact of bus routes using a composite route score that factors in impact, efficiency and equity.
This efficiency study was ordered in 2024 by the governor and the General Assembly as a condition of granting RIPTA the $15 million it needed to continue operating without service cuts. But Gov. Dan McKee's proposed budget released in January left RIPTA facing a $32.6 million budget deficit because of cost increases due to inflation, COVID relief money running out, and finally paying drivers a living wage.
Health care and RIPTA prevail in lawmakers' revised fiscal 2026 budget
The House version of the fiscal 2026 budget released Tuesday night includes an estimated $15 million in annual funding for RIPTA, about half of what the agency needs to maintain current service. This all but guarantees that the results of the efficiency study will be used to guide route cancellations and service reductions. While the additional revenue will help, the agency cannot 'fat-trim' its way out of what now is a $17 million hole. Riders who rely on routes that scored lowest in the new study are likely to be most at risk.
Consider the 40 bus, which received low scores, especially on impact. The 40 serves Butler Hospital, connecting riders with not only urgent psychiatric care, but also many outpatient mental health and substance abuse programs. How is this not one of the most impactful routes? Likewise, the 66 bus received an even lower score than the 40, but it provides vital service to students and staff of CCRI and URI, not to mention being a one-seat ride to the airport. Yet another example is the 73, even lower on the list, one of the only buses that serves Central Falls, the most densely populated area in our state with the largest percentage of people without driver's licenses.
The data points do not tell these stories. To their credit, the writers of the report go out of their way to acknowledge that the data does not account for the real-world impact of low scoring routes.
'Some routes may perform lower in terms of ridership,' the report states, 'yet still benefit the network as a whole by feeding passengers into other routes, serving vulnerable populations and providing service coverage in transit-dependent neighborhoods.'
The report attempts to strike an unachievable balance, ranking routes like they are players to be cut or traded, while calling low performing routes 'lifelines' and highlighting how any cuts to service will undoubtedly harm individual users. It even suggests maintaining service on the lowest scoring route, the 88, which links subsidized housing for the elderly at Simmons Village with the Cranston Walmart, because it connects people to vital services.
Reducing service would also undermine RIPTA's progress on the Transit Master Plan. For example, the plan calls for more crosstown and rural routes, yet many of these routes receive low scores in the efficiency study draft. For example, Pawtucket's crosstown routes received lower scores, as well as some of the express (X) buses, like the 59X in North Smithfield and Lincoln. Yet the report also noted the importance of the route as it connects commuters to employment centers. Furthermore, park-and-ride users are often 'choice' riders, who can choose to drive or take the bus. One rider noted that choice riders have a larger impact on climate change since most of their trips would otherwise be made by driving.
The report attempts to strike an unachievable balance, ranking routes like they are players to be cut or traded.
The report also highlights how important the fixed-route service is in achieving our climate goals. It states that fixed route service lowered statewide vehicle trips by 11.5 million trips and vehicle miles traveled by over 43 million miles. Furthermore, emissions of volatile organic compounds were reduced by 96% and greenhouse gas emissions by 25%. These numbers show how RIPTA is essential to reduction in carbon emissions required by the Act on Climate. Any reductions of fixed route service would lower the environmental impact of RIPTA and increase vehicle trips and emissions.
Any reductions on fixed route service will also impact service for people with disabilities, known as RIDE. Federal law mandates that RIDE service must be offered to disabled people within ¾ mile of a bus route. However, if that fixed route service is cut, all of the RIDE service along the route will be cut as well. The RIDE service also aids in our climate goals, further lowering statewide vehicle trips by 69,400 and reduction of vehicle miles traveled by over 1.7 million miles.One RIDE participant of the 'RIDE anywhere' pilot program noted, 'Up until the program began, I was housebound for 5 years.'
The data points in the report tell one story. Yet the underlying message of the report actually illustrates the importance of the totality of the services that RIPTA provides. Its narrative is that we should provide RIPTA with the full $32.6 million that covers each and every one of the routes. In order to achieve our economic and climate goals, we must fully fund RIPTA and provide them with a sustainable funding source for the future, so they are not underfunded year after year.
Funding RIPTA will ensure that the routes in 37 out of 39 municipalities in Rhode Island will continue along with vital service for those with disabilities, students and commuters. Otherwise, we face service cuts that will devastate rural and suburban service and cut off transportation access for those with disabilities. Cutting service in the name of efficiency abandons the very people transit is meant to serve. To build a fair, connected Rhode Island, we must fully fund RIPTA's $32.6 million shortfall and commit to equity as a guiding principle — not a secondary goal. Public transit isn't just about numbers; it's about people.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
How did John MacArthur die? What we know about pastor's cause of death
John MacArthur, the longtime pastor of a megachurch in Southern California and founder of a syndicated media ministry, died July 14 after being hospitalized with pneumonia. "Our hearts are heavy, yet rejoicing, as we share the news that our beloved pastor and teacher John MacArthur has entered into the presence of the Savior," MacArthur's media ministry, Grace to You, wrote on social media. "This evening, his faith became sight." MacArthur, 86, was the pastor at Grace Community Church, a nondenominational congregation in Sun Valley, California, a post he held since 1969. Tom Patton, another pastor at Grace Community Church, said at a July 13 service that MacArthur had been hospitalized after contracting pneumonia. USA TODAY has reached out to Grace Community Church. MacArthur's cause of death has not been announced, though he had been hospitalized with pneumonia in his final days, Patton said. "This week pastor John contracted pneumonia," Patton said. "He was admitted into the hospital and may be in the presence of the Lord soon." A message on Grace Community Church's website noted the same about MacArthur's condition. "Last week, Pastor John unexpectedly contracted pneumonia, and the Lord took him home on Monday, July 14," the message said. A message on Grace to You's website said MacArthur died "after dealing with some significant health challenges dating back to early 2023." "Just as the details of John's death are new to you, they are new to us as well. We probably have many of the same thoughts and feelings that you do," Grace to You's website said. USA TODAY has reached out to the Los Angeles County Medical Examiner's office for more information. Grace to You's website also said there are currently no details about services for MacArthur. John MacArthur was a pastor and author known for leading Grace Community Church in Sun Valley, California, and for his work with the media ministry Grace to You. He was also the longtime president and chancellor of The Master's University, a private Christian university in Santa Clarita, California, and founder of The Master's Seminary in Los Angeles. MacArthur became the pastor at Grace Community Church in 1969 after graduating from Talbot Theological Seminary in California, according to his leadership bio. Throughout his career, he also wrote nearly 400 books. Like some other preachers across the U.S., MacArthur entered the public spotlight during the COVID-19 pandemic when he hosted large gatherings despite local policies limiting congregations to small numbers outside. "At the center of Dr. MacArthur's ministry was an unwavering commitment to declare God's truth, and Pastor John preached the Word in season and out of season," Grace Community Church's website says. "Even in recent years, though beset with health challenges, he persisted in teaching, leading, and investing in the ministries the Lord had entrusted to him." In addition to his wife of 61 years, Patricia, MacArthur is survived by four children, fifteen grandchildren and nine great-grandchildren. Contributing: James Powel and Natalie Neysa Alund, USA TODAY Melina Khan is a national trending reporter for USA TODAY. She can be reached at This article originally appeared on USA TODAY: How did John MacArthur die? Grace Community Church announces his death


USA Today
8 hours ago
- USA Today
How did John MacArthur die? What we know about pastor's cause of death
John MacArthur, the longtime pastor of a megachurch in Southern California and founder of a syndicated media ministry, died July 14 after being hospitalized with pneumonia. "Our hearts are heavy, yet rejoicing, as we share the news that our beloved pastor and teacher John MacArthur has entered into the presence of the Savior," MacArthur's media ministry, Grace to You, wrote on social media. "This evening, his faith became sight." MacArthur, 86, was the pastor at Grace Community Church, a nondenominational congregation in Sun Valley, California, a post he held since 1969. Tom Patton, another pastor at Grace Community Church, said at a July 13 service that MacArthur had been hospitalized after contracting pneumonia. USA TODAY has reached out to Grace Community Church. John MacArthur cause of death: What we know MacArthur's cause of death has not been announced, though he had been hospitalized with pneumonia in his final days, Patton said. "This week pastor John contracted pneumonia," Patton said. "He was admitted into the hospital and may be in the presence of the Lord soon." A message on Grace Community Church's website noted the same about MacArthur's condition. "Last week, Pastor John unexpectedly contracted pneumonia, and the Lord took him home on Monday, July 14," the message said. A message on Grace to You's website said MacArthur died "after dealing with some significant health challenges dating back to early 2023." "Just as the details of John's death are new to you, they are new to us as well. We probably have many of the same thoughts and feelings that you do," Grace to You's website said. USA TODAY has reached out to the Los Angeles County Medical Examiner's office for more information. Grace to You's website also said there are currently no details about services for MacArthur. Who was John MacArthur? About his pastoral career John MacArthur was a pastor and author known for leading Grace Community Church in Sun Valley, California, and for his work with the media ministry Grace to You. He was also the longtime president and chancellor of The Master's University, a private Christian university in Santa Clarita, California, and founder of The Master's Seminary in Los Angeles. MacArthur became the pastor at Grace Community Church in 1969 after graduating from Talbot Theological Seminary in California, according to his leadership bio. Throughout his career, he also wrote nearly 400 books. Like some other preachers across the U.S., MacArthur entered the public spotlight during the COVID-19 pandemic when he hosted large gatherings despite local policies limiting congregations to small numbers outside. "At the center of Dr. MacArthur's ministry was an unwavering commitment to declare God's truth, and Pastor John preached the Word in season and out of season," Grace Community Church's website says. "Even in recent years, though beset with health challenges, he persisted in teaching, leading, and investing in the ministries the Lord had entrusted to him." In addition to his wife of 61 years, Patricia, MacArthur is survived by four children, fifteen grandchildren and nine great-grandchildren. Contributing: James Powel and Natalie Neysa Alund, USA TODAY Melina Khan is a national trending reporter for USA TODAY. She can be reached at


New York Post
8 hours ago
- New York Post
Scientists crack the code on new vaccine for deadly plague bacteria
Israeli researchers have developed a new vaccine that is '100% effective' against bacteria that is deadly to humans. The announcement came from Tel Aviv University, which teamed up with the Israel Institute for Biological Research to create the mRNA-based vaccine, the first to protect against bacteria. 'In the study, we show that our mRNA vaccine provides 100% protection against pneumonic plague (a severe lung infection), which is considered the most dangerous form of the disease,' study co-lead Professor Dan Peer, director of the Laboratory of Precision NanoMedicine at Tel Aviv University, told Fox News Digital. 6 Illustration of the Yersinia pestis bacteria. nobeastsofierce – 'Yersinia pestis, the causative agent of plague, is considered a highly lethal infectious bacterium, against which no approved vaccine exists.' This bacterium is so lethal, even at small doses, that it's been classified as a 'Tier 1 select agent' by the CDC and is considered a 'potential bioterror weapon,' according to Peer. 'Within a week, all unvaccinated animals died, while those vaccinated with our vaccine remained alive and well,' the team reported, noting that a single dose provided full protection after two weeks. The findings were published in the journal Science Advances. Before this study, mRNA vaccines were only shown to protect against viruses, such as COVID-19, but not bacteria, according to Tel Aviv University's Dr. Edo Kon, who co-led the study. 'Until now, scientists believed that mRNA vaccines against bacteria were biologically unattainable,' said Kon in the announcement. 'In our study, we proved that it is, in fact, possible to develop mRNA vaccines that are 100% effective against deadly bacteria.' 6 A photo of Prof. Dan Peer, Dr. Inbal Hazan-Halefy, and Shani Benarroch. Tel Aviv University While vaccines for viruses trigger human cells to produce viral proteins, which then train the immune system to protect against them, that same method hasn't been effective for bacteria. Instead, the scientists used a different method to release bacterial proteins that successfully created a 'significant immune response.' 'To enhance the bacterial protein's stability and make sure that it does not disintegrate too quickly inside the body, we buttressed it with a section of human protein,' they wrote. 'By combining the two breakthrough strategies, we obtained a full immune response.' Dr. Jacob Glanville, CEO of Centivax, a San Francisco biotechnology company, reiterated the importance of the study. 6 Yersinia pestis vaccine vial and syringe. iStock 'This is distinct from research in coronavirus, influenza and cancer, which have so far been driving mRNA vaccine applications,' Glanville, who was not part of the research team, told Fox News Digital. The study shows how mRNA technologies can be rapidly applied to 'novel threat areas,' he confirmed. 'Following blowback from the mandates and rare but admittedly problematic side effects related to initial COVID-19 vaccines, mRNA as a platform has faced additional scrutiny to make sure that the next generation of vaccines to emerge from it has learned the lessons from the initial vaccines, and improved upon them,' Glanville told Fox News Digital. 'This research demonstrates yet another large application area for the technology.' Potential limitations 6 Microscopic image of Yersinia pestis bacteria. Getty Images The primary limitation of the study, according to Peer, is that the vaccine's effectiveness was shown in mice. 'As with any pre-clinical study, it needs to be evaluated in a clinical study in order to assess its effectiveness in humans,' he told Fox News Digital. In addition, the experimental mRNA vaccine is based on the 'lipid nanoparticle (LNP) mRNA vaccine platform' that was recently approved for COVID-19 vaccines, Peer noted, which requires 'cold chain logistics' (a supply chain that uses refrigeration). 'Nevertheless, extensive studies are performed in our lab, focusing on lipid formulation stability optimization that will enable room-temperature storage,' the researcher added. Looking ahead 6 The primary limitation of the study, according to Peer, is that the vaccine's effectiveness was shown in mice. motortion – The goal is for this new technology to fast-track vaccines for bacterial diseases, according to the researchers. This could be particularly beneficial for pathogenic (disease-causing) and antibiotic-resistant bacteria. 'Due to excessive use of antibiotics over the last few decades, many bacteria have developed resistance to antibiotics, reducing the effectiveness of these important drugs,' said Peer. 'Consequently, antibiotic-resistant bacteria already pose a real threat to human health worldwide. Developing a new type of vaccine may provide an answer to this global problem.' As Peer pointed out, the quick development of the COVID-19 vaccine was based on years of mRNA research for similar viruses. 6 The goal is for this new technology to fast-track vaccines for bacterial diseases, according to the researchers. AP 'If tomorrow we face some kind of bacterial pandemic, our study will provide a pathway for quickly developing safe and effective mRNA vaccines.' As this was a pre-clinical proof-of-concept study, Peer noted that several major milestones still need to be fulfilled before this vaccine could be considered for commercial rollout. However, he believes that in an emergency situation, the vaccine could be scaled up and prepared in a 'relatively short time.' Peer concluded, 'Beyond addressing the threat of plague outbreaks and potential bioterrorism, this study opens the door to developing mRNA vaccines against other antibiotic-resistant bacteria, offering a powerful new strategy to combat rising antimicrobial resistance and improve global pandemic preparedness.' The study was supported by the European Research Council, the Israel Institute for Biological Research and the Shmunis Family Foundation.